SDHB and gastrointestinal stromal tumor: Importantly, SDH-deficient GIST showed better clinical outcome than other WT-GIST.131Taken together, the previous information indicates that regorafenib may be more advantageous than IM for advanced WT-GIST patients as upfront therapy.